%0 Journal Article
%T Adverse Events following AstraZeneca COVID-19 Vaccination: A Case Study in Abidjan, Côte d’Ivoire
%A Chiay&#233
%A Claire Antoinette Yapo-Crezoit
%A Samuel Boahene
%A Mireille Dosso
%J Open Journal of Immunology
%P 11-15
%@ 2162-4526
%D 2024
%I Scientific Research Publishing
%R 10.4236/oji.2024.142002
%X <b>Introduction</b><b>: </b>Pharmaceutical companies have boosted vaccine production following the global COVID-19 pandemic. In C&#244;te d&#8217;Ivoire, the first vaccination campaign with the AstraZeneca vaccine began on March 1, 2021, as part of the Covax program. Despite the positive benefit/risk balance, the adverse effects of vaccination should not be minimized. <b>Objective:</b> To identify adverse events of AstraZeneca&#8217;s COVID-19 vaccination for better management.<b> </b><b>Materials and Methods:</b> This is a case of a 57-year-old obese (BMI = 39 kg/m<sup>2</sup>) female health care worker who experienced adverse events in March 2021 after the second dose of AstraZeneca vaccine administered 4 weeks apart. These were subject to mandatory case reporting. <b>Results: </b>Major post-vaccination events occurred in a noisy systemic picture with parameters showing significant disturbances. Biological surveillance remains costly and makes the accountability of the vaccine complex. <b>Conclusion:</b> Vaccination remains the ultimate weapon in the fight against endemic diseases but should not overshadow the reporting of adverse events.
%K Adverse Events
%K Post-Second Immunization
%K AstraZeneca Vaccine
%K Abidjan
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=133817